Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.45 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.45 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602935 | 0.82 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL3608584 | 0.81 | PIK3CG (0.51) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Hydrochloric Acid SCHEMBL7142142 | 0.80 | PIK3CD (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL7141961 | 0.80 | PIK3CG (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL13074374 | 0.80 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL3596697 | 0.80 | XIAP (0.47) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| Hydrochloric Acid SCHEMBL7140582 | 0.79 | XIAP (0.46) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL48462 | 0.78 | PIK3CG (0.69) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL11080713 | 0.76 | XIAP (0.48) | PIK3CDPIK3CGPIK3CAPIK3CBPI4KB | |
| SCHEMBL3606518 | 0.75 | MEN1 (0.50) | PIK3CDPIK3CGPIK3CAPIK3CBXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| CN-1080720-C | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-03-13 | — | — | CN | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| CN-1224718-A | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 1999-08-04 | — | — | CN | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | PIK3CD 3749/4885PIK3CG 3998/4885PIK3CA 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.